Explore more publications!

Attor­ney Gen­er­al Pax­ton Sues Big Phar­ma Com­pa­nies Bris­tol-Myers Squibb and Sanofi for Mak­ing Bil­lions While Harm­ing Amer­i­cans and Fail­ing to Dis­close Plavix’s Ineffectiveness

Attorney General Ken Paxton filed a lawsuit against pharmaceutical companies Sanofi and Bristol-Myers Squibb for failing to disclose that their drug Plavix did not work effectively for certain patients.

Plavix, whose generic form is clopidogrel bisulfate, is intended to prevent heart attacks, strokes, and blood clots by helping stop platelets in the blood from clumping together. However, the companies failed to warn patient-consumers and their prescribing physicians that Plavix had diminished or no effect for many patients, particularly Black, East Asian, and Pacific Islander patients. Defendants’ deceit resulted in patients being prescribed a medication that was substantially inadequate or inappropriate, in violation of the Texas Health Care Program Fraud Prevention Act.  

Defendants made billions off of Plavix by falsely marketing its product as effective and hiding information that showed its diminished performance in patients. Defendants prioritized profits even if it meant putting patients’ lives at risk. The lawsuit highlights that Sanofi’s actions are in clear violation of Texas’s Health Care Program Fraud Prevention Act and consumer protection laws. 

“It’s despicable how Big Pharma puts lives at risk by refusing to be honest with patients,” said Attorney General Paxton. “We are going to make Sanofi and Bristol-Myers Squibb pay a heavy cost for their utter lack of regard or concern for Americans and the company’s clear violations of Texas law. Every healthcare and pharmaceutical company should be put on notice that anyone who endangers the health of Americans absolutely will be held accountable.”

To read the lawsuit, click here.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions